MEDISTIM ASA (MEDI.OL) Stock Fundamental Analysis
Europe - OSL:MEDI - NO0010159684 - Common Stock
260 NOK
+8 (+3.17%)
MEDI gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 62 industry peers in the Health Care Equipment & Supplies industry. MEDI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDI is valued quite expensive, but it does show an excellent growth. These ratings would make MEDI suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year MEDI was profitable.
In the past year MEDI had a positive cash flow from operations.
In the past 5 years MEDI has always been profitable.
Each year in the past 5 years MEDI had a positive operating cash flow.
1.2 Ratios
The Return On Assets of MEDI (24.51%) is better than 96.67% of its industry peers.
MEDI's Return On Equity of 34.17% is amongst the best of the industry. MEDI outperforms 96.67% of its industry peers.
The Return On Invested Capital of MEDI (32.05%) is better than 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MEDI is significantly above the industry average of 8.76%.
The last Return On Invested Capital (32.05%) for MEDI is above the 3 year average (24.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.51% | ||
| ROE | 34.17% | ||
| ROIC | 32.05% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
1.3 Margins
MEDI's Profit Margin of 20.67% is amongst the best of the industry. MEDI outperforms 90.00% of its industry peers.
In the last couple of years the Profit Margin of MEDI has remained more or less at the same level.
MEDI has a Operating Margin of 26.96%. This is amongst the best in the industry. MEDI outperforms 93.33% of its industry peers.
In the last couple of years the Operating Margin of MEDI has remained more or less at the same level.
MEDI has a Gross Margin of 80.94%. This is amongst the best in the industry. MEDI outperforms 95.00% of its industry peers.
MEDI's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.96% | ||
| PM (TTM) | 20.67% | ||
| GM | 80.94% |
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDI is creating value.
MEDI has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, MEDI has more shares outstanding
Compared to 1 year ago, MEDI has a worse debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of MEDI is 0.14, which is an excellent value as it means it would take MEDI, only 0.14 years of fcf income to pay off all of its debts.
MEDI has a better Debt to FCF ratio (0.14) than 91.67% of its industry peers.
MEDI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.06, MEDI belongs to the best of the industry, outperforming 81.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | N/A |
ROIC/WACC3.75
WACC8.54%
2.3 Liquidity
A Current Ratio of 3.14 indicates that MEDI has no problem at all paying its short term obligations.
MEDI has a better Current ratio (3.14) than 81.67% of its industry peers.
MEDI has a Quick Ratio of 1.73. This is a normal value and indicates that MEDI is financially healthy and should not expect problems in meeting its short term obligations.
MEDI's Quick ratio of 1.73 is fine compared to the rest of the industry. MEDI outperforms 71.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
MEDI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.76%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.96% on average over the past years.
MEDI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.85%.
MEDI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.12% yearly.
EPS 1Y (TTM)25.76%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%24.21%
Revenue 1Y (TTM)17.85%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%16.67%
3.2 Future
The Earnings Per Share is expected to grow by 11.78% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.00% on average over the next years. This is quite good.
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MEDI is valuated quite expensively with a Price/Earnings ratio of 36.26.
MEDI's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.89, MEDI is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 33.28, the valuation of MEDI can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as MEDI.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.99, MEDI is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.26 | ||
| Fwd PE | 33.28 |
4.2 Price Multiples
MEDI's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, MEDI is valued a bit cheaper than the industry average as 65.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.33 | ||
| EV/EBITDA | 24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDI does not grow enough to justify the current Price/Earnings ratio.
MEDI has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.14
PEG (5Y)4.55
EPS Next 2Y13.46%
EPS Next 3Y11.78%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.38%, MEDI has a reasonable but not impressive dividend return.
MEDI's Dividend Yield is rather good when compared to the industry average which is at 2.23. MEDI pays more dividend than 85.00% of the companies in the same industry.
MEDI's Dividend Yield is comparable with the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.38% |
5.2 History
The dividend of MEDI is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
MEDI's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y13.46%
EPS Next 3Y11.78%
OSL:MEDI (10/24/2025, 7:00:00 PM)
260
+8 (+3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners60.12%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap4.77B
Revenue(TTM)634.52M
Net Income(TTM)131.14M
Analysts82.5
Price Target260.1 (0.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.38% |
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)21.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.26 | ||
| Fwd PE | 33.28 | ||
| P/S | 7.51 | ||
| P/FCF | 31.33 | ||
| P/OCF | 31.33 | ||
| P/B | 12.42 | ||
| P/tB | 15.04 | ||
| EV/EBITDA | 24 |
EPS(TTM)7.17
EY2.76%
EPS(NY)7.81
Fwd EY3.01%
FCF(TTM)8.3
FCFY3.19%
OCF(TTM)8.3
OCFY3.19%
SpS34.6
BVpS20.93
TBVpS17.28
PEG (NY)2.14
PEG (5Y)4.55
Graham Number58.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.51% | ||
| ROE | 34.17% | ||
| ROCE | 41.59% | ||
| ROIC | 32.05% | ||
| ROICexc | 41.86% | ||
| ROICexgc | 53.13% | ||
| OM | 26.96% | ||
| PM (TTM) | 20.67% | ||
| GM | 80.94% | ||
| FCFM | 23.98% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
ROICexc(3y)39.99%
ROICexc(5y)39.99%
ROICexgc(3y)48.52%
ROICexgc(5y)48.01%
ROCE(3y)32.29%
ROCE(5y)33.19%
ROICexgc growth 3Y-6.52%
ROICexgc growth 5Y0.36%
ROICexc growth 3Y-8.47%
ROICexc growth 5Y0.04%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
F-Score6
Asset Turnover1.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.11 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 77.82% | ||
| Profit Quality | 116.05% | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | N/A |
F-Score6
WACC8.54%
ROIC/WACC3.75
Cap/Depr(3y)105.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.78%
Cap/Sales(5y)N/A
Profit Quality(3y)91.83%
Profit Quality(5y)103.03%
High Growth Momentum
Growth
EPS 1Y (TTM)25.76%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%24.21%
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue 1Y (TTM)17.85%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%16.67%
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A
EBIT growth 1Y32.5%
EBIT growth 3Y4.07%
EBIT growth 5Y7.86%
EBIT Next Year34.29%
EBIT Next 3Y15.73%
EBIT Next 5YN/A
FCF growth 1Y59.35%
FCF growth 3Y-0.65%
FCF growth 5Y12.16%
OCF growth 1Y59.35%
OCF growth 3Y3.75%
OCF growth 5Y12.23%
MEDISTIM ASA / MEDI.OL FAQ
What is the ChartMill fundamental rating of MEDISTIM ASA (MEDI.OL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDI.OL.
What is the valuation status of MEDISTIM ASA (MEDI.OL) stock?
ChartMill assigns a valuation rating of 3 / 10 to MEDISTIM ASA (MEDI.OL). This can be considered as Overvalued.
Can you provide the profitability details for MEDISTIM ASA?
MEDISTIM ASA (MEDI.OL) has a profitability rating of 9 / 10.
What is the valuation of MEDISTIM ASA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MEDISTIM ASA (MEDI.OL) is 36.26 and the Price/Book (PB) ratio is 12.42.
Can you provide the expected EPS growth for MEDI stock?
The Earnings per Share (EPS) of MEDISTIM ASA (MEDI.OL) is expected to grow by 16.97% in the next year.